Premature cardiovascular disease in young women with heterozygous familial hypercholesterolemia.
Heterozygous familial hypercholesterolemia is associated with elevated low-density lipoprotein cholesterol levels and the development of premature cardiovascular disease. Despite this general statement, data regarding the incidence of cardiovascular disease in young women with familial hypercholesterolemia are lacking. In this review, information of age-specific incidence, risk factors and therapeutic avenues in women with heterozygous familial hypercholesterolemia are discussed.
van der Graaf
Anouk
A
Academic Medical Centre, Dept.Vascular Medicine, Meibergdreef 9 (room F4-159.2) 1105 AZ, Amsterdam, The Netherlands. a.vandergraaf@amc.uva.nl
Hutten
Barbara A
BA
Kastelein
John J P
JJ
Vissers
Maud N
MN
D000328:Adult; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000209:etiology* / Q000517:prevention & control; D008078:Cholesterol, LDL / Q000097:blood; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D006938:Hyperlipoproteinemia Type II / Q000150:complications* / Q000188:drug therapy / Q000235:genetics; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D012737:Sex Factors
D000924:Anticholesteremic Agents; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors